BridgeBio Oncology Therapeutics (BBOT) Stock Forecast, Price Target & Predictions
BBOT Stock Forecast
BridgeBio Oncology Therapeutics (BBOT) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $19.00, with a high of $22.00 and a low of $15.00. This represents a 708.51% increase from the last price of $2.35.
BBOT Stock Rating
BridgeBio Oncology Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).
Buy
BBOT Price Target Upside V Benchmarks
| Type | Name | Upside |
|---|---|---|
| Stock | BridgeBio Oncology Therapeutics | 708.51% |
| Sector | Healthcare Stocks | 15.45% |
| Industry | Biotech Stocks | 41.48% |
Price Target Trends
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 8 |
| Avg Price Target | - | $19.00 | $20.63 |
| Last Closing Price | $2.35 | $2.35 | $2.35 |
| Upside/Downside | - | 708.51% | 777.87% |
Ratings Trends
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell | Total |
|---|---|---|---|---|---|---|
| Nov, 26 | 4 | 8 | - | - | - | 12 |
| Oct, 26 | 4 | 8 | - | - | - | 12 |
| Sep, 26 | 4 | 7 | - | - | - | 11 |
| Aug, 26 | 4 | 7 | - | - | - | 11 |
| Jul, 26 | 3 | 7 | - | - | - | 10 |
Analyst Price Target Forecasts
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 09, 2026 | Sean McCutcheon | Raymond James | $22.00 | $8.52 | 158.22% | 836.17% |
| Sep 09, 2026 | Stifel Nicolaus | $15.00 | $8.86 | 69.30% | 538.30% | |
| Sep 09, 2026 | Canaccord Genuity | $20.00 | $8.86 | 125.73% | 751.06% | |
| May 11, 2026 | John Newman | Canaccord Genuity | $23.00 | $7.66 | 200.26% | 878.72% |
| Feb 10, 2026 | Laura Prendergast | Stifel Nicolaus | $23.00 | $10.84 | 112.18% | 878.72% |
| Jan 09, 2026 | Raymond James | $24.00 | $13.30 | 80.45% | 921.28% | |
| Jan 08, 2026 | Morgan Stanley | $18.00 | $12.92 | 39.32% | 665.96% | |
| Dec 05, 2025 | Morgan Stanley | $20.00 | $11.54 | 73.31% | 751.06% | |
| Sep 17, 2025 | Leerink Partners | $25.00 | $10.79 | 131.70% | 963.83% | |
| Sep 15, 2025 | Robert Burns | H.C. Wainwright | $27.00 | $9.73 | 177.49% | 1048.94% |
Analyst Rating Forecasts
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | Overweight | Overweight | hold |
| Oct 20, 2026 | Oppenheimer | Outperform | Outperform | hold |
| Sep 09, 2026 | Raymond James | Outperform | Outperform | hold |
| Jul 08, 2026 | UBS | Overweight | downgrade | |
| Jan 09, 2026 | Raymond James | Outperform | initialise | |
| Dec 05, 2025 | Morgan Stanley | Overweight | initialise | |
| Sep 15, 2025 | H.C. Wainwright | Buy | initialise | |
| Sep 04, 2025 | Oppenheimer | Outperform | initialise | |
| Aug 15, 2025 | Piper Sandler | Overweight | initialise | |
| Aug 13, 2025 | Cantor Fitzgerald | Overweight | initialise |
Financial Forecast
EPS Forecast
Annual
| Dec 24 | Dec 25 | Dec 26 | Dec 27 | |
|---|---|---|---|---|
| Reported | $0.46 | $-4.30 | - | - |
| Avg Forecast | $-268.56 | $-2.28 | $-2.11 | $-2.46 |
| High Forecast | $-268.56 | $-1.38 | $-1.36 | $-2.46 |
| Low Forecast | $-268.56 | $-3.45 | $-3.52 | $-2.46 |
| Surprise % | -100.17% | 88.60% | - | - |
Revenue Forecast
Annual
| Dec 24 | Dec 25 | Dec 26 | Dec 27 | |
|---|---|---|---|---|
| Reported | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
Net Income Forecast
Annual
| Dec 24 | Dec 25 | Dec 26 | Dec 27 | |
|---|---|---|---|---|
| Reported | $-74.28M | $-134.04M | - | - |
| Avg Forecast | $-4.47B | $-40.18M | $-40.59M | $-40.92M |
| High Forecast | $-4.47B | $-22.96M | $-22.62M | $-40.92M |
| Low Forecast | $-4.47B | $-57.39M | $-58.56M | $-40.92M |
| Surprise % | -98.34% | 233.64% | - | - |